Multiphasic

Results point to Enspryng® (satralizumab) as effective in blocking IL-6 receptor and MOGAD-related inflammationA process of the immune system that involves chemicals released by immune cells (i.e. white blood cells) inducing localized heat, swelling, redness, and pain to an area that occurs when tissue becomes damaged or infected from a pathogen, and usually results in the desctruction and removal of the pathogen and/or healing to the tissue. In the case of myelin oligodendrocyte glycoprotein antibody disease (MOGAD), inflammation is the result of the incorrect targeting of the myelin oligodendrocyte glycoprotein (MOG) by the immune system, resulting in damage to myelin sheaths. Washington, DC – (April 21, 2026) The MOGA type of protein involved in cell adhesion. Present throughout myelin sheaths. Project is thrilled

The MOGA type of protein involved in cell adhesion. Present throughout myelin sheaths. Project is honored to be featured by Johns Hopkins Medicine in a recent article highlighting advances in understanding myelin oligodendrocyte glycoprotein antibody diseaseOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease  

The MOG Project’s Research for Rare program has awarded our 2025 MOGADOften referred to as MOGAD, Anti-MOG, MOG Ab+, MOG Antibody Disease, MOG Associated Antibody Disease, MOG positive disease   global research grants: the Apollo Grant and the Accelerator Grant. These grants are